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Background. The National Kidney Foundation’s Kidney Dis-
ease Outcomes Quality Initiative (NKF-K/DOQITM) has es-
tablished guidelines for treatment of secondary hyperparathy-
roidism (HPT). The ability of cinacalcet HCl (SensiparTM) treat-
ment to improve achievement of target levels of parathyroid
hormone (PTH), calcium, phosphorus, and calcium-phosphorus
product (Ca × P) was investigated in subjects on dialysis with
secondary HPT.
Methods. Data were combined from three placebo-
controlled, double-blind, 26-week studies with similar design
that randomized 1136 subjects on dialysis to receive traditional
therapy plus cinacalcet or placebo. Oral cinacalcet was titrated
from 30 to 180 mg/day. Achievement of K/DOQI goals was de-
termined for each treatment group overall and for subgroups
defined by baseline intact PTH (iPTH) and Ca × P levels.
Results. Cinacalcet-treated subjects were more likely to
achieve a mean iPTH ≤300 pg/mL (31.8 pmol/L) than were con-
trol subjects on traditional therapy (56% vs. 10%, P < 0.001).
Cinacalcet-treated subjects were more likely to achieve con-
centrations of serum calcium within 8.4 to 9.5 mg/dL (2.10–2.37
mmol/L) and serum phosphorus within 3.5 to 5.5 mg/dL (1.13–
1.78 mmol/L) than were control subjects (49% vs. 24% and 46%
vs. 33%, P < 0.001 for each). Cinacalcet also improved achieve-
ment of Ca × P < 55 mg2/dL2 (4.44 mmol2/L2) and concurrent
achievement of Ca × P < 55 mg2/dL2 (4.44 mmol2/L2) and iPTH
≤300 pg/mL (31.8 pmol/L) (65% vs. 36% and 41% vs. 6%, P <
0.001 for each).
Conclusion. In subjects on dialysis with secondary
HPT, cinacalcet facilitates achievement of the K/DOQI-
recommended targets for PTH, calcium, phosphorus, and
Ca × P.
Key words: calcimimetic, cinacalcet HCl, NKF-K/DOQI guidelines, sec-
ondary hyperparathyroidism (HPT), chronic kidney disease (CKD),
dialysis.
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Secondary hyperparathyroidism (HPT) is a common
complication of chronic kidney disease (CKD). Complex
interactions among serum calcium, phosphorus, and 1,25-
dihydroxyvitamin D3 (calcitriol) are associated with pro-
gressive increases in parathyroid hormone (PTH) when
the glomerular filtration rate (GFR) falls below approx-
imately 60 mL/min/1.73 m2 [1–3]. In patients with CKD
on dialysis, elevated PTH is associated with increased
mortality, considerable musculoskeletal morbidity, and
bone pain [4–8]. Secondary HPT is also complicated
by increased calcium-phosphorus product (Ca × P) lev-
els, which may be exacerbated by the use of vitamin D
sterols and calcium-based phosphate binders. Ca × P lev-
els are elevated [>55 mg2/dL2 (4.44 mmol2/L2)] in ap-
proximately 50% of patients on dialysis [4], and are as-
sociated with an increased risk of cardiac, visceral, and
vascular calcification [9–11] and cardiovascular mortality
[4, 5].
Recognizing the clinical significance of secondary
HPT among patients with CKD, the National Kidney
Foundation’s Kidney Disease Outcomes Quality Ini-
tiative (NKF-K/DOQITM) has recently published Clin-
ical Practice Guidelines for Bone Metabolism and
Disease [12]. The K/DOQI guidelines for stage 5 CKD
(estimated GFR <15 mL/min/1.73m2 or on dialysis) rec-
ommend treatment goals for intact PTH [iPTH, 150 to
300 pg/mL (15.9 to 31.8 pmol/L)], total corrected serum
calcium [8.4 to 9.5 mg/dL (2.10 to 2.37 mmol/L)], serum
phosphorus [3.5 to 5.5 mg/dL (1.13 to 1.78 mmol/L)], and
Ca × P [<55 mg2/dL2 (4.44 mmol2/L2)] [12].
Traditional therapies for treating secondary HPT and
associated disorders of mineral metabolism, including
dietary phosphate restriction, oral phosphate binders,
calcium supplementation, and vitamin D sterols, are in-
adequate for many patients [13–16]. Dietary phosphate
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Table 1. Key study design characteristics for studies A, B, and C
Study A Study B Study C
Eligibility criteria iPTH ≥300 pg/mL; serum calcium
≥8.4 mg/dL; hemodialysis
duration >3 months
iPTH ≥300 pg/mL; serum calcium
≥8.4 mg/dL; hemodialysis
duration >3 months
iPTH ≥300 pg/mL; serum calcium
≥8.4 mg/dL; hemodialysis or
peritoneal dialysis >1 month
Study duration 26 weeks; 12 weeks dose titration,
14 weeks efficacy assessment
26 weeks; 12 weeks dose titration,
14 weeks efficacy assessment
26 weeks; 16 weeks dose titration,
10 weeks efficacy assessment
Regions of study conduct United States, Canada European community, Australia United States, Canada, Australia
Study dates Dec 2001-Dec 2002 Feb 2002-Jan 2003 May 2002-March 2003
Randomization ratio 1:1Cinacalcet:control 1:1Cinacalcet:control 3:1Cinacalcet:control
Number of patients enrolled Cinacalcet205 Control205 Cinacalcet165 Control166 Cinacalcet294 Control101
Randomization stratification Baseline iPTH level and baseline
Ca × P level
Baseline iPTH level and baseline
Ca × P level
Dialysis modality; hemodialysis
patients were further stratified
according to baseline iPTH level
Cinacalcet dose range 30 to 180 mg once daily 30 to 180 mg once daily 30 to 180 mg once daily
Target iPTH 100 to 250 pg/mL 100 to 250 pg/mL 100 to 250 pg/mL
restriction is associated with low adherence, and may
compromise dietary protein intake [3, 13]; calcium-based
phosphate binders may lead to gastrointestinal discom-
fort [12] and contribute to hypercalcemia [17, 18]; some
non–calcium-containing phosphate binders may be as-
sociated with gastrointestinal discomfort and metabolic
acidosis [12, 19], and vitamin D sterols may lead to hyper-
calcemia and hyperphosphatemia as a result of increased
intestinal absorption of both calcium and phosphorus [10,
11, 20]. It is recognized, therefore, that achievement of the
K/DOQI targets with these therapeutic options is chal-
lenging [10].
The calcimimetic cinacalcet HCl (SensiparTM), here-
after called cinacalcet, is a new treatment option for sec-
ondary HPT that has been shown to reduce PTH while
simultaneously lowering serum calcium, phosphorus, and
Ca × P levels in study subjects undergoing hemodialy-
sis [21–23]. In light of the recently published K/DOQI
guidelines, we analyzed the efficacy of cinacalcet in fa-
cilitating achievement of the K/DOQI targets in subjects
on dialysis with secondary HPT. The data were collected
in three geographically diverse, but similarly designed
double-blind, placebo-controlled, randomized clinical
trials.
METHODS
Subjects
A total of 1136 subjects were enrolled in the three
studies (designated studies A, B, and C) included in this
analysis. The studies were conducted at 182 centers in
North America, Europe, and Australia. The Institutional
Review Board for each study center approved the study
protocol and amendments, and written informed consent
was obtained from study subjects before the initiation of
any study-specific procedures. Key aspects of each study
are defined in Table 1.
The studies had similar enrollment criteria (Table 1).
Patients were excluded if they had a history of an unstable
medical condition, or had required a change in dose or
brand of vitamin D in the preceding 30 days. Additionally,
in studies A and B, patients were excluded if they had
changed their dose or brand of phosphate binder, oral
calcium supplement, or dialysate calcium concentration
in the preceding 30 days.
Study design
The three studies included in this analysis were of sim-
ilar design and duration (Table 1, Fig. 1). Study sub-
jects were randomized in a 1:1 (studies A and B) or
3:1 (study C) ratio to receive cinacalcet (665 subjects)
or placebo (471 subjects). In studies A and B, random-
ization was stratified by mean baseline iPTH level [300
to 500, 501 to 800, or >800 pg/mL (31.8 to 53.0, 53.1 to
84.8, or >84.8 pmol/L)] and by baseline Ca × P level
[≤70 or >70 mg2/dL2 (≤5.65 or >5.65 mmol2/L2)]. In
study C, randomization was stratified by dialysis modal-
ity, and randomization of hemodialysis patients was fur-
ther stratified by baseline iPTH level. Each 26-week,
randomized, double-blind, placebo-controlled study con-
sisted of a 12-week (studies A and B) or 16-week (study
C) dose-titration phase and a 14-week (studies A and
B) or 10-week (study C) evaluation phase. Blood sam-
ples for the measurement of iPTH, serum calcium, serum
phosphorus, and Ca × P were obtained at least ev-
ery 2 weeks during the dose-titration and evaluation
phases. Subjects initially received 30 mg cinacalcet (or
placebo) orally, once daily. Doses were increased every 3
or 4 weeks, provided the subject’s previous iPTH con-
centration was ≥200 pg/mL (21.2 pmol/L), and serum
calcium was ≥7.8 mg/dL (≥1.95 mmol/L). Dose titra-
tion continued until the iPTH was reduced to <200
pg/mL (21.2 pmol/L) or until the highest dose of study
drug (180 mg/day cinacalcet or placebo) was reached.
If subjects experienced symptoms attributed to hypocal-
cemia or an adverse event considered to be related to
the study medication, or if iPTH concentrations were
<100 pg/mL (10.6 pmol/L) on two or more consecutive
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Titration phasea
(12 weeks [studies A and B]
or 16 weeks [study C])
Efficacy assessment phasea,b
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aStudy drug dose could also have been reduced according to
protocol-specified rules.
bDose titration was also allowed every 3 or 4 weeks.
cThe placebo and cinacalcet treatment groups followed the same
titration rules.
Fig. 1. Integrated efficacy study design
schema.
visits, study drug (cinacalcet or placebo) was stopped, or
the dose reduced.
Concomitant medication
Throughout the studies, subjects continued to receive
their secondary HPT therapies, including vitamin D
sterols and phosphate binders, if prescribed. Except dur-
ing the screening phase, phosphate binders or oral cal-
cium supplements could be adjusted at any time at the
discretion of the treating physician. Vitamin D sterols
were held constant, with the following exceptions spec-
ified by the protocol. If iPTH concentrations increased
by ≥50% from baseline for three consecutive visits, or if
a subject experienced symptoms attributed to hypocal-
cemia and/or a serum calcium concentration <8.4 mg/dL
(<2.10 mmol/L), despite an increase in oral calcium, the
vitamin D dose could be increased. If iPTH concentra-
tions were <100 pg/mL (10.6 pmol/L) for three consecu-
tive study visits and the subject was receiving the lowest
dose of study medication, vitamin D doses could be re-
duced or withheld. Reductions in doses of vitamin D were
also permitted if serum calcium was ≥11 mg/dL (≥2.74
mmol/L), serum phosphorus was ≥6.5 mg/dL (≥2.10
mmol/L), or Ca × P was ≥70 mg2/dL2 (5.65 mmol2/L2).
Outcomes measures
For this secondary analysis, the efficacy of cinacalcet
during the evaluation phase was determined by assess-
ing the proportion of subjects with a mean iPTH value
≤300 pg/mL (31.8 pmol/L), mean serum calcium 8.4 to
9.5 mg/dL (2.10 to 2.37 mmol/L), mean serum phosphorus
3.5 to 5.5 mg/dL (1.13 to 1.78 mmol/L), mean Ca × P <55
mg2/dL2 (4.44 mmol2/L2), and both a mean iPTH value
≤300 pg/mL (31.8 pmol/L) and mean Ca × P <55 mg2/dL2
(4.44 mmol2/L2) during the evaluation phase. Results are
presented for the total population and by subgroups as-
signed according to baseline iPTH and Ca × P levels. The
iPTH ≤300 pg/mL (31.8 pmol/L) target (the upper limit
of the K/DOQI-recommended range) was used for these
analyses rather than the K/DOQI range of 150 to 300 pg/
mL (15.9 to 31.8 pmol/L) because the phase 3 studies
were initiated before the release of the K/DOQI guide-
lines [12], and were designed to evaluate achievement
of iPTH ≤250 pg/mL (26.5 pmol/L) by titrating to iPTH
levels of 100 to 250 pg/mL (10.6 to 26.5 pmol/L). The
achievement of this primary end point [mean iPTH ≤250
pg/mL (26.5 pmol/L)] has been previously reported for
studies A and B [23]. Baseline and evaluation phase val-
ues for iPTH, serum calcium, serum phosphorus, and Ca
× P are reported as medians because the values were
not normally distributed, and were skewed toward the
upper end of the range, reflecting the high percentage
of patients with severe secondary HPT in these stud-
ies. Values for the doses of cinacalcet used by subjects
achieving the iPTH ≤300 pg/mL (31.8 pmol/L) target
were not normally distributed and are expressed as me-
dians. The safety of cinacalcet was assessed by evalu-
ating the frequency, severity, and relationship to treat-
ment of all reported adverse events, as well as changes
in laboratory parameters and vital signs compared with
placebo.
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Statistical analysis
Subject-level data were combined from the three stud-
ies. A logistic regression model that included treatment
group and study design as independent variables and the
primary end point of the studies (achievement of iPTH
≤250 pg/mL) as the dependent variable indicated that
the study itself was not significantly associated with iPTH
reduction (P = 0.32), and there was no significant inter-
action between study and treatment group (P = 0.50).
Therefore, treatment effect did not differ between stud-
ies, and it was considered appropriate to combine data
from the three studies.
Baseline demographic and laboratory values, ex-
pressed as N (%) or median [interquartile range (Q1,
Q3)] were obtained during the screening period for all
randomized subjects. Efficacy analyses included all sub-
jects with at least one value recorded during the eval-
uation phase (547 cinacalcet, 409 placebo). For cate-
gorical variables, the Cochran-Mantel-Haenszel (CMH)
test [24], stratified by study, was used to examine differ-
ences between treatment groups. Results are expressed as
the percentage of subjects achieving iPTH ≤300 pg/mL
(31.8 pmol/L), Ca × P < 55 mg2/dL2 (4.44 mmol2/L2),
both iPTH ≤300 pg/mL (31.8 pmol/L) and Ca × P < 55
mg2/dL2 (4.44 mmol2/L2), or the K/DOQI target ranges
for serum calcium and phosphorus, or as median [in-
terquartile range (Q1, Q3)] for biochemical measures.
The safety analysis included all subjects who received at
least one dose of study drug (656 cinacalcet, 470 placebo).
All statistical calculations were performed by using SAS
software (version 8.2, SAS Institute, Cary, NC, USA), and
two-tailed P values < 0.05 were considered statistically
significant.
RESULTS
Of the 1136 subjects enrolled in the studies, 1126 (99%)
received at least one dose of study medication (656
cinacalcet, 470 placebo), 956 subjects (84%) entered the
evaluation phase, and 840 subjects (74%) completed the
studies. At study entry, no clinically meaningful differ-
ences in demographics, biochemical laboratory parame-
ters, or use of concomitant medications existed between
the cinacalcet and control groups (Table 2). More than
20% of subjects overall had severe secondary HPT (iPTH
>800 pg/mL) at baseline, with study C having the highest
fractional enrollment of these patients (35%).
Efficacy of cinacalcet in achieving K/DOQI
treatment goals
iPTH. In accordance with the study enrollment crite-
ria, almost all subjects had iPTH values at baseline that
exceeded the recommended K/DOQI target. After treat-
ment, 56% of subjects treated with cinacalcet achieved
Table 2. Baseline demographics and biochemistriesa
Cinacalcet Control Total
(N = 665) (N = 471) (N = 1136)
Sex
Female 258 (39) 176 (37) 434 (38)
Male 407 (61) 295 (63) 702 (62)
Race
White 324 (49) 265 (56) 589 (52)
Black 245 (37) 155 (33) 400 (35)
Other 96 (14) 51 (11) 147 (13)
Age
<65 510 (77) 335 (71) 845 (74)
=65 155 (23) 136 (29) 291 (26)
Dialysis modalityb
Hemodialysis 631 (95) 459 (97) 1090 (96)
Peritoneal dialysis 34 (5) 12 (3) 46 (4)
iPTH pg/mL 596 (429, 863) 564 (411, 785)
Serum calcium mg/dL 9.9 (9.3, 10.4) 9.8 (9.4, 10.5)
Serum phosphorus 6.0 (5.1, 7.1) 6.2 (5.1, 7.1)
mg/dL
Ca × P mg2/dL2 60.2 (49.0, 70.5) 61.3 (50.7, 70.8)
Vitamin D sterol use 437 (66) 318 (68) 755 (66)
Phosphate binder use 617 (93) 438 (93) 1055 (93)
Abbreviations are: PTH, parathyroid hormone; Ca, corrected total serum
calcium; P, serum phosphorus; Ca × P, calcium-phosphorus product. Note: To
convert PTH in pg/mL to ng/L, multiply by 1.0; calcium in mg/dL to mmol/L,
multiply by 0.2495; phosphorus in mg/dL to mmol/L, multiply by 0.3229; Ca × P
in mg2/dL2 to mmol2/L2, multiply by 0.0807.
aValues are N (%) or median (Q1, Q3).
bDifference between cinacalcet and control groups is the result of the 3 to 1
cinacalcet to control stratification in study C, which was the only study in which
both peritoneal dialysis and hemodialysis patients were enrolled.
mean iPTH concentrations at or below the upper limit of
the K/DOQI target range [≤300 pg/mL (31.8 pmol/L)],
compared with 10% of control subjects (P < 0.001;
Table 3). The median (Q1, Q3) iPTH concentrations
during the evaluation phase were 258 (160, 524) pg/mL
[27.3 (17.0, 55.5) pmol/L] and 605 (410, 854) pg/mL [64.1
(43.5, 90.5) pmol/L] for cinacalcet and control subjects,
respectively (Fig. 2A), compared with baseline values of
596 (429, 863) pg/mL [63.2 (45.5, 91.5) pmol/L] and 564
(411, 785) pg/mL [59.8 (43.6, 83.2)] pmol/L, respectively.
Thirty-three percent of cinacalcet-treated subjects and
9% of control subjects had a mean iPTH value of 150 to
300 pg/mL (15.9 to 31.8 pmol/L), corresponding to the
full K/DOQI range. Thirty-seven percent of cinacalcet-
treated subjects had mean iPTH levels of 100 to 250 pg/
mL (10.6 to 26.5 pmol/L), the target range specified by
the titration guidelines in the original studies.
Ca × P. At baseline, 37% and 34% of cinacalcet-
treated and control subjects, respectively, had mean Ca ×
P values below the K/DOQI target of 55 mg2/dL2
(4.44 mmol2/L2). After treatment, 65% of subjects re-
ceiving cinacalcet achieved the Ca × P target, compared
with 36% in the control group (P < 0.001; Table 3). Dur-
ing the evaluation phase, the median (Q1, Q3) Ca × P
concentration was 48.1 (39.3, 60.4) mg2/dL2 [3.88 (3.17,
4.87) mmol2/L2] in the cinacalcet-treated group, but re-
mained above the K/DOQI target at 58.7 (51.3, 67.0)
mg2/dL2 [4.74 (4.14, 5.41) mmol2/L2] in the control group
(Fig. 2B).
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Table 3. Overall achievement of the K/DOQI targets at baseline and
during the evaluation phase in cinacalcet and control subjects
Cinacalcet Control
K/DOQI target (N = 547) (N = 409)
iPTH ≤300 pg/mLb N (%) N (%)
Baseline 2 (<1) 2 (<1) P valuea
Post treatment 307 (56) 42 (10) <0.001
Serum calcium 8.4–9.5 mg/dL
Baseline 176 (32) 133 (33)
Post treatment 270 (49) 100 (24) <0.001
Serum phosphorus 3.5–5.5 mg/dL
Baseline 179 (33) 126 (31)
Post treatment 250 (46) 136 (33) <0.001
Ca × P <55 mg2/dL2
Baseline 203 (37) 139 (34)
Post treatment 357 (65) 148 (36) <0.001
iPTH ≤300 pg/mLb and Ca × P <55 mg2/dL2
Baseline 0 (0) 0 (0)
Post treatment 224 (41) 25 (6) <0.001
Abbreviations are: iPTH, intact parathyroid hormone; Ca × P, calcium-
phosphorus product. Note: To convert PTH in pg/mL to pmol/L, multiply by
0.105; calcium in mg/dL to mmol/L, multiply by 0.2495; phosphorus in mg/dL to
mmol/L, multiply by 0.3229; Ca × P in mg2/dL2 to mmol2/L2, multiply by 0.0807.
aComparing achievement of the K/DOQI target between cinacalcet HCl and
control during the evaluation phase.
bK/DOQI target for PTH is 150 to 300 pg/mL.
Serum phosphorus. Approximately one third of sub-
jects in each treatment group had mean serum phospho-
rus values within the K/DOQI range [3.5 to 5.5 mg/dL
(1.13 to 1.78 mmol/L)] at baseline (Table 3). After treat-
ment, 46% of subjects given cinacalcet achieved a mean
serum phosphorus level within this range, compared with
33% of control subjects (P < 0.001, Table 3). The me-
dian (Q1, Q3) serum phosphorus level during the eval-
uation phase was 5.3 (4.4, 6.4) mg/dL [1.71 (1.42, 2.07)
mmol/L] in the cinacalcet group, compared with 5.9 (5.1,
6.7) mg/dL [1.91 (1.65, 2.16) mmol/L] in the control group
(Fig. 2C).
Serum calcium. At baseline, 32% and 33% of subjects
in the cinacalcet and control groups, respectively, had
mean serum calcium concentrations within the K/DOQI
target range [8.4 to 9.5 mg/dL (2.10 to 2.37 mmol/L), ad-
justed for serum albumin; Table 2]. Following treatment
with cinacalcet, a significantly greater proportion of sub-
jects achieved the K/DOQI target range for serum cal-
cium, compared with control subjects (49% vs. 24%, P <
0.001; Table 3). The median (Q1, Q3) serum calcium con-
centration during the evaluation phase decreased to 9.1
(8.5, 9.7) mg/dL [2.27 (2.12, 2.42) mmol/L] in the cinacal-
cet group, compared with a slight increase to 9.9 (9.5, 10.4)
mg/dL [2.47 (2.37, 2.59) mmol/L] in the control group
(Fig. 2D).
iPTH and Ca × P. The combined end point of iPTH
≤300 pg/mL (31.8 pmol/L) and Ca × P < 55 mg2/dL2
(4.44 mmol2/L2) was achieved by 41% of cinacalcet-
treated subjects compared with only 6% of control
subjects (P < 0.001; Fig. 3, Table 3). In addition, the
proportion of cinacalcet-treated subjects achieving this
combined end point continued to increase throughout
the study (Fig. 3).
Achievement of K/DOQI goals in individual studies
Achievement of the four key K/DOQI treatment goals
for secondary HPT was also examined in the individual
studies. Achievement was comparable among studies and
similar to the combined analysis (Figs. 4A to C).
Subgroup analysis
Achievement of K/DOQI targets was analyzed for
subgroups defined by baseline iPTH and Ca × P. Af-
ter treatment, 81 and 60% of cinacalcet-treated subjects
in the iPTH 300 to 500 and 501 to 800 pg/mL (31.8 to
53.0 and 53.1 to 84.8 pmol/L) subgroups achieved an
iPTH ≤300 pg/mL (31.8 pmol/L) compared with 21 and
4%, respectively, of control subjects (Fig. 5A). Among
those with baseline iPTH >800 pg/mL (84.8 pmol/L),
a level at which parathyroidectomy is often recom-
mended, 22% of subjects receiving cinacalcet achieved
the iPTH ≤300 pg/mL (31.8 pmol/L) target after only
26 weeks of therapy, compared with 1% of control
subjects. Similar proportions of cinacalcet-treated sub-
jects (46% to 60%) achieved an iPTH ≤300 pg/mL
(31.8 pmol/L) regardless of Ca × P subgroup (Fig. 5B).
There was no effect of gender or duration of dialysis (vin-
tage) on the PTH suppressive effects of cinacalcet.
In all subgroups, the proportion of subjects achieving
the Ca × P <55 mg2/dL2 (4.44 mmol2/L2) target was
greater in the cinacalcet group compared with the con-
trol group. Among subjects with a Ca × P ≤70 mg2/dL2
(5.65 mmol2/L2) at baseline, 71% to 80% achieved the
K/DOQI target for Ca × P in the cinacalcet subgroups
during the evaluation phase, and the magnitude of re-
sponse was similar for all iPTH subgroups [300 to 500,
501 to 800, and >800 pg/mL (31.8 to 53.0, 53.1 to 84.8, and
>84.8 pmol/L)]. By comparison, in control subjects who
had Ca × P >70 mg2/dL2 (5.65 mmol2/L2) at baseline,
the percentage of subjects who achieved the Ca × P tar-
get declined as iPTH increased (61%, 38%, and 25% for
the respective baseline iPTH subgroups). In subjects with
Ca × P levels >70 mg2/dL2 (5.65 mmol2/L2), cinacalcet
treatment enabled 37% of subjects to reduce their Ca ×
P value to <55 mg2/dL2 (4.44 mmol2/L2), compared with
10% of control subjects (Fig. 5B). Trends across sub-
groups for achievement of K/DOQI targets for serum
calcium and phosphorus were similar to those observed
for achievement of Ca × P (Fig. 5A and B).
Concomitant therapy
The proportions of cinacalcet-treated subjects with a
decrease, no change, or increase in vitamin D sterol dose
from baseline compared with the evaluation phase were
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Fig. 2. Median (A) iPTH, (B) Ca × P, (C) serum phosphorus, and (D) serum calcium levels of subjects in the cinacalcet or control groups at each
study visit. Error bars indicate interquartile ranges, Q1 and Q3. The shaded region for each graph indicates the K/DOQI target range. BL, baseline.
generally similar to the proportions of control subjects
with these changes (Table 4). Changes in calcium-based
phosphate binders and sevelamer were also similar, with
the exception that more control subjects required an in-
crease in sevelamer (Table 4). For studies A and C, there
was uniformity of calcium-based phosphate binder brand
type, allowing for data on elemental calcium intake to be
calculated. The median (10%, 90% range) change in ele-
mental calcium intake from binder per day was 0 (–500,
500) mg and 0 (–501, 334) mg in the cinacalcet and con-
trol arms, respectively. More subjects in the cinacalcet
group initiated calcium-based binders during the study
compared with control (13% vs. 8%, P = 0.02); elemen-
tal calcium intake for these subjects was similar in both
groups. Overall, the estimated exogenous calcium intake
from phosphate binders was essentially unchanged in
cinacalcet-treated and control subjects. Median doses of
vitamin D and sevelamer were also similar between treat-
ment groups at baseline and end of study.
Safety data
Cinacalcet, at doses ranging from 30 to 180 mg once
per day, was generally well tolerated by study subjects.
For the 307 subjects who achieved a mean iPTH ≤300
pg/mL (31.8 pmol/L), 79% were receiving doses of 30 or
60 mg of cinacalcet at the time of their first iPTH measure-
ment ≤300 pg/mL, and the median dose of cinacalcet was
30 mg.
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Adverse events that occurred ≥5% more frequently
in cinacalcet-treated subjects compared with control sub-
jects were nausea (31% vs. 19%, respectively) and vomit-
ing (27% vs. 15%, respectively). These events were gener-
ally mild to moderate in severity and brief in duration. In
the cinacalcet group, only 8% and 9% of subjects had two
or more episodes of nausea or vomiting, respectively. A
similar number of serious adverse events occurred in each
group (29% vs. 31% in the cinacalcet and control groups,
respectively). Fifteen percent of cinacalcet-treated sub-
jects withdrew from the study because of adverse events,
compared with 8% of control subjects. Withdrawals due
to adverse events in the cinacalcet group were primarily
due to nausea or vomiting. A total of 29 subjects died
during the studies (2% of the cinacalcet group and 3% of
the control group); none of the deaths were considered
to be related to treatment.
In the combined studies, serum calcium concentrations
below 7.5 mg/dL (1.88 mmol/L) occurred on at least two
consecutive measurements in 5% of cinacalcet-treated
subjects and <1% of control subjects. These values were
rarely associated with symptoms, and returned to a value
above 8.0 mg/dL (2.00 mmol/L) after modifying the doses
of calcium supplements, phosphate binders, vitamin D, or
cinacalcet. One subject in each treatment group withdrew
because of hypocalcemia.
DISCUSSION
Secondary HPT is associated with significant morbidity
and mortality [4–8]. Evidence suggests that maintaining
metabolic parameters within the K/DOQI target ranges
is of significant clinical relevance [12], and recent obser-
vational data demonstrate that the K/DOQI treatment
goals are not easily achieved, or maintained, with tradi-
tional therapeutic options for secondary HPT [10]. This
secondary analysis of three large randomized, placebo-
controlled studies of nearly identical design demonstrates
that treatment with cinacalcet effectively reduces iPTH,
calcium, phosphorus, and Ca × P to below the upper lim-
its of the recommended K/DOQI target ranges in sub-
jects on dialysis with secondary HPT. Nearly all subjects
had iPTH values >300 pg/mL (31.8 pmol/L) at baseline,
consistent with eligibility criteria, and approximately two
thirds of subjects had baseline values for serum calcium,
phosphorus, and Ca × P above the K/DOQI targets. Sig-
nificantly, more than half of subjects treated with cinacal-
cet achieved a mean iPTH≤300 pg/mL (31.8 pmol/L), and
41% simultaneously achieved both a mean iPTH level
≤300 pg/mL (31.8 pmol/L) and a mean Ca × P value <55
mg2/dL2 (4.44 mmol2/L2), reflecting the ability of cinacal-
cet to reduce both iPTH and Ca × P. Cinacalcet also
increased achievement of K/DOQI targets in subjects
with iPTH >800 pg/mL (84.8 pmol/L) and in those with
elevated Ca × P, despite a relatively short treatment time,
thereby demonstrating its utility in subjects who have
laboratory values that preclude the use of vitamin D.
Furthermore, cinacalcet was highly effective in bringing
subjects with less severe abnormalities in PTH and Ca ×
P into target, confirming its efficacy in mild, as well as in
moderate to severe, secondary HPT.
Elevated serum calcium and phosphorus concentra-
tions may predispose patients to soft-tissue and vascular
calcification [9, 25] and an increased risk of cardiovascular
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Fig. 4. Achievement of K/DOQI targets during the evaluation phase of each individual study. (A) Study A, (B) Study B, and (C) Study C. The
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and all-cause mortality [4, 5]. In this study, cinacalcet con-
trolled PTH while simultaneously reducing calcium and
phosphorus, the most challenging hurdle in achieving the
K/DOQI guidelines [5]. In contrast, most studies evaluat-
ing treatment of secondary HPT with vitamin D demon-
strate an increase in serum calcium and/or phosphorus
[26–29]. Vitamin D is effective in suppressing PTH and,
therefore, likely decreases the efflux of calcium and phos-
phorus from bone [14]. However, these potential positive
effects may be outweighed by enhanced intestinal ab-
sorption of calcium and phosphate, which may lead to a
net increase in calcium and phosphorus in the serum [10,
11, 18]. In contrast, both calcium and phosphorus con-
centrations decrease in response to cinacalcet treatment,
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Table 4. Changes in concomitant medication use
Dose changesa Cinacalcet Control
Proportion of patients with change in
vitamin D sterol doseb
Decrease 14% 15%
No change 27% 30%
Increase 11% 12%
Proportion of patients with change in calcium-based
phosphate binder dosec
Decrease 3% 6%
No change 26% 24%
Increase 16% 17%
Proportion of patients with change in sevelamer dose
Decrease 5% 1%
No change 31% 25%
Increase 24% 36%
aChanges represent mean over efficacy-assessment phase compared to
baseline for patients using vitamin D at both baseline and the efficacy-assessment
phase.
bExcludes patients using more than 1 type of vitamin D sterol.
cExcludes patients using more than 1 type of calcium-based phosphate binder.
most likely as a result of decreased mineral efflux from
bone in response to reductions in PTH, without an ad-
ditional intestinal source of mineral [21, 22]. Based on
the data demonstrating similar changes in vitamin D and
phosphate binder use in the two arms, reductions in cal-
cium and phosphorus were likely attributable to cinacal-
cet therapy.
These analyses provide information on the achieve-
ment of K/DOQI targets after intervention with cinacal-
cet treatment in a large number of geographically di-
verse subjects. Nonetheless, some important limitations
should be noted. These studies were 6 months in du-
ration, and longer-term maintenance of subjects within
K/DOQI target ranges must be demonstrated, including
effects on bone. Preliminary results indicate that cinacal-
cet is effective in reducing iPTH and Ca × P levels in
subjects for up to 3 years [abstract; Moe et al, J Am
Soc Nephrol 14:463A, 2003], suggesting the effects of
cinacalcet are sustained over time. In addition, because
the maximal reduction of iPTH in response to cinacalcet
occurs approximately 4 hours after dosing [26], the mea-
surement of iPTH at approximately 24 hours after dos-
ing may underestimate the total iPTH suppression that
occurs.
The impact of several aspects of the study design on
the achievement of the K/DOQI targets is also notable.
Because the K/DOQI guidelines were only recently de-
veloped, the dosing algorithm for iPTH was not prospec-
tively designed to achieve the K/DOQI target range. In-
stead, the phase 3 study target for iPTH was selected as
100 to 250 pg/mL (10.6 to 26.5 pmol/L), consistent with
clinical practice at the time of protocol development [30–
32]. Thus, some subjects may have been titrated to iPTH
levels below the lower end of the K/DOQI target [150
pg/mL (15.9 pmol/L)], while remaining within the range
accepted by the protocol. Many factors can influence the
optimal PTH level; K/DOQI recommends iPTH 150 to
300 (15.9 to 31.8 pmol/L) as a value supported by avail-
able evidence to represent adequate control of PTH in
patients on dialysis [12]. Finally, because the study pro-
tocols limited changes in vitamin D sterols during the
study, the achievement of K/DOQI targets for Ca × P,
calcium, and phosphorus reported here may underesti-
mate actual achievement of these targets when cinacal-
cet is used in clinical practice without restrictions on
vitamin D use.
CONCLUSION
Significantly more cinacalcet-treated subjects achieved
K/DOQI targets for PTH, calcium, phosphorus, and Ca
× P compared with control subjects on traditional ther-
apy, across a broad population and regardless of severity
of disease. More effective control of secondary HPT fa-
cilitated by cinacalcet may ultimately improve outcomes
among patients with CKD.
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